LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 7 von insgesamt 7

Suchoptionen

  1. Artikel: Nutritional intervention in ADHD.

    Newmark, Sanford C

    Explore (New York, N.Y.)

    2009  Band 5, Heft 3, Seite(n) 171–174

    Mesh-Begriff(e) Attention Deficit Disorder with Hyperactivity/diet therapy ; Attention Deficit Disorder with Hyperactivity/etiology ; Child ; Dietary Supplements ; Food Additives/adverse effects ; Humans ; Nutrition Therapy ; Risk Factors
    Chemische Substanzen Food Additives
    Sprache Englisch
    Erscheinungsdatum 2009-05
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2183945-1
    ISSN 1550-8307
    ISSN 1550-8307
    DOI 10.1016/j.explore.2009.03.006
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6635: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: ADHD and food sensitivity.

    Newmark, Sanford C

    Alternative therapies in health and medicine

    2002  Band 8, Heft 3, Seite(n) 18; author reply 18

    Mesh-Begriff(e) Attention Deficit Disorder with Hyperactivity/etiology ; Attention Deficit Disorder with Hyperactivity/therapy ; Child ; Complementary Therapies/methods ; Food Hypersensitivity/complications ; Food Hypersensitivity/therapy ; Humans ; Randomized Controlled Trials as Topic
    Sprache Englisch
    Erscheinungsdatum 2002-05
    Erscheinungsland United States
    Dokumenttyp Comment ; Letter
    ZDB-ID 1225073-9
    ISSN 1078-6791
    ISSN 1078-6791
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4504: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism.

    Weber, Wendy / Newmark, Sanford

    Pediatric clinics of North America

    2007  Band 54, Heft 6, Seite(n) 983–1006; xii

    Abstract: Complementary and alternative medical (CAM) therapies are commonly used by parents for their children who have attention deficit hyperactivity disorder (ADHD) or autism spectrum disorders. The use of these therapies is well documented, yet the evidence ... ...

    Abstract Complementary and alternative medical (CAM) therapies are commonly used by parents for their children who have attention deficit hyperactivity disorder (ADHD) or autism spectrum disorders. The use of these therapies is well documented, yet the evidence of the safety and efficacy of these treatments in children is limited. This article describes the current evidence-based CAM therapies for ADHD and autism, focusing on nutritional interventions; natural health products, including essential fatty acids, vitamins, minerals, and other health supplements; biofeedback; and reducing environmental toxins. The CAM evidence in ADHD is addressed, as is the CAM literature in autism.
    Mesh-Begriff(e) Attention Deficit Disorder with Hyperactivity/diet therapy ; Attention Deficit Disorder with Hyperactivity/epidemiology ; Attention Deficit Disorder with Hyperactivity/therapy ; Autistic Disorder/therapy ; Child ; Complementary Therapies/methods ; Food Hypersensitivity/epidemiology ; Homeopathy/methods ; Humans ; Massage ; Minerals ; Phytotherapy ; Vitamins ; Yoga
    Chemische Substanzen Minerals ; Vitamins
    Sprache Englisch
    Erscheinungsdatum 2007-12
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 215711-1
    ISSN 1557-8240 ; 0031-3955
    ISSN (online) 1557-8240
    ISSN 0031-3955
    DOI 10.1016/j.pcl.2007.09.006
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Um IV Zs.147: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

    Gehn Eva / Newmark Sanford / Zappia Irene / Hensley Andrea / Ingram Julie / Mitchell Jessica / Geis Elizabeth / Baral Matthew / Adams James B / Rubin Robert A / Mitchell Ken / Bradstreet Jeff / El-Dahr Jane

    BMC Clinical Pharmacology, Vol 9, Iss 1, p

    Part B - Behavioral results

    2009  Band 17

    Abstract: Abstract Background This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods Phase 1 involved 65 children with ASD who ... ...

    Abstract Abstract Background This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R 2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94). Conclusion Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.
    Schlagwörter Therapeutics. Pharmacology ; RM1-950 ; Medicine ; R ; DOAJ:Therapeutics ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Thema/Rubrik (Code) 150
    Sprache Englisch
    Erscheinungsdatum 2009-10-01T00:00:00Z
    Verlag BioMed Central
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  5. Artikel ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

    Gehn Eva / Newmark Sanford / Zappia Irene / Hensley Andrea / Ingram Julie / Mitchell Jessica / Geis Elizabeth / Baral Matthew / Adams James B / Rubin Robert A / Mitchell Ken / Bradstreet Jeff / El-Dahr Jane

    BMC Clinical Pharmacology, Vol 9, Iss 1, p

    Part A - Medical results

    2009  Band 16

    Abstract: Abstract Background This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. Methods Phase 1 involved 65 children who received one round of DMSA (3 days). Participants ... ...

    Abstract Abstract Background This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. Methods Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation. Conclusion Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.
    Schlagwörter Therapeutics. Pharmacology ; RM1-950 ; Medicine ; R ; DOAJ:Therapeutics ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Sprache Englisch
    Erscheinungsdatum 2009-10-01T00:00:00Z
    Verlag BioMed Central
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  6. Artikel ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.

    Adams, James B / Baral, Matthew / Geis, Elizabeth / Mitchell, Jessica / Ingram, Julie / Hensley, Andrea / Zappia, Irene / Newmark, Sanford / Gehn, Eva / Rubin, Robert A / Mitchell, Ken / Bradstreet, Jeff / El-Dahr, Jane

    BMC clinical pharmacology

    2009  Band 9, Seite(n) 17

    Abstract: Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.: Methods: Phase 1 involved 65 children with ASD who received ... ...

    Abstract Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.
    Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
    Results: The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94).
    Conclusion: Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.
    Mesh-Begriff(e) Adaptation, Psychological/drug effects ; Aging ; Autistic Disorder/classification ; Autistic Disorder/complications ; Autistic Disorder/drug therapy ; Chelating Agents/adverse effects ; Chelating Agents/therapeutic use ; Child ; Child Behavior/drug effects ; Child, Preschool ; Drug Administration Schedule ; Glutathione/blood ; Heavy Metal Poisoning, Nervous System/complications ; Humans ; Metals, Heavy/toxicity ; Metals, Heavy/urine ; Parents/psychology ; Psychiatric Status Rating Scales ; Regression Analysis ; Succimer/adverse effects ; Succimer/therapeutic use ; Surveys and Questionnaires ; Treatment Outcome
    Chemische Substanzen Chelating Agents ; Metals, Heavy ; Succimer (DX1U2629QE) ; Glutathione (GAN16C9B8O)
    Sprache Englisch
    Erscheinungsdatum 2009-10-23
    Erscheinungsland England
    Dokumenttyp Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041488-2
    ISSN 1472-6904 ; 1472-6904
    ISSN (online) 1472-6904
    ISSN 1472-6904
    DOI 10.1186/1472-6904-9-17
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

    Adams, James B / Baral, Matthew / Geis, Elizabeth / Mitchell, Jessica / Ingram, Julie / Hensley, Andrea / Zappia, Irene / Newmark, Sanford / Gehn, Eva / Rubin, Robert A / Mitchell, Ken / Bradstreet, Jeff / El-Dahr, Jane

    BMC clinical pharmacology

    2009  Band 9, Seite(n) 16

    Abstract: Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.: Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants ... ...

    Abstract Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.
    Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
    Results: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
    Conclusion: Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.
    Mesh-Begriff(e) Administration, Oral ; Autistic Disorder/blood ; Autistic Disorder/drug therapy ; Autistic Disorder/urine ; Blood Cell Count/methods ; Child ; Child, Preschool ; Double-Blind Method ; Female ; Glutathione/blood ; Glutathione/urine ; Humans ; Male ; Metals/blood ; Metals/urine ; Succimer/administration & dosage ; Succimer/adverse effects ; Treatment Outcome
    Chemische Substanzen Metals ; Succimer (DX1U2629QE) ; Glutathione (GAN16C9B8O)
    Sprache Englisch
    Erscheinungsdatum 2009-10-23
    Erscheinungsland England
    Dokumenttyp Clinical Trial, Phase I ; Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041488-2
    ISSN 1472-6904 ; 1472-6904
    ISSN (online) 1472-6904
    ISSN 1472-6904
    DOI 10.1186/1472-6904-9-16
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang